Research and development spending rose 14.3% compared to Q2 2024, reflecting a busy clinical pipeline, while the net loss (GAAP) increased to $10.4 million. These 10 stocks could mint the next wave of ...

Key Points GAAP EPS loss of $9.09 was narrower than the expected $9.24 per share for Q2 2025, a minor outperformance. Research and development expenses (GAAP) rose 29.2% to $2.2 million, reflecting ...

Denifanstat met all primary and secondary endpoints in Phase 3 clinical trial in moderate to severe acne conducted by license ...

Positive Phase 2 results for BX211 demonstrated >40% wound size reduction vs. placebo in diabetic foot osteomyelitis patients; Planning underway for potential registrational study Nature Communication ...

First patient dosed with CUE-102 for recurrent glioblastoma multiforme (rGBM) at Dana-Farber Cancer Institute (DFCI) BOSTON, ...

As the dust settles on its successful takeover of Awakn Life Sciences, investors are starting to appreciate the potential of ...

Expanded strategic partnership with The Scripps Research Institute to advance proof-of-concept studies and further develop its program combining systemic DNase I with CAR T-cell therapies ...

Pb]VMT-α-NET study update presented at the 2025 ASCO Annual Meeting, based on updated interim results from a Phase 1/2a study in neuroendocrine tumors. As of the April 30, 2025 data cut-off date: Four ...

Anavex faces dilution risk from its $150M ATM facility, high cash burn, and lack of revenue. Click here to see why AVXL stock ...

Oric Pharmaceuticals’ previously announced plan to focus resources on its two most advanced oncology drugs comes with a sting in its tail—the therapeutic-resistance-focused biotech is laying off 20 | ...

Good afternoon, ladies and gentlemen, and welcome to the Inovio Second Quarter 2025 Financial Results Conference Call. [Operator Instructions] This call is being recorded on Tuesday, August 12, 2025.

Bayer will partner with Kumquat Biosciences to develop Kumquat’s KRAS G12D inhibitor, which could generate $1.3 billion-plus for the San Diego biotech.